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DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS: SELECTION OF A 
CORE SET OF VARIABLES AND A FIRST STEP IN THE 
DEVELOPMENT OF A DISEASE ACTIVITY SCORE
M. C. W. CREEM ERS, M. A. VAN T  HOF,* M. J. A. M. FR A N SSEN ,f L. B. A. VAN DE PUTTE, 
F. W. J. GRIBNAU:!: and P. L. C. IVI. VAN RIEL
SUMMARY
A large number of variables are available for the assessment of disease activity in ankylosing spondylitis (AS). The aim of this 
study was to evaluate the validity of commonly used variables, to select a core set of valid variables for disease activity and 
finally to compute an AS disease activity score (AS-DAS). Data from two longitudinal studies were used. Principal component 
analysis and reliability analysis resulted in 1 1 factors: cervical mobility, lumbar flexion, subjective complaints, functional index 
(FI), enthesis index (El), inflammatory response, IgA, IgM, root joints, swollen joints and spinal mobility. Based on 
discriminating power, reproducibility and correlation with disease duration, seven single variables were selected. In a subsequent 
discriminant analysis, an AS-DAS was computed of five variables, i.e. subjective complaints, FI, HI, root joints and C-reactive 
protein, which should be validated in the future. A core set of process variables solves the problem of multiple testing in clinical 
trials, and improves comparability.
K ey w o r d s : Disease activity, Ankylosing spondylitis, Outcome, Validity.
T h e  evaluation of disease activity in ankylosing 
spondylitis (AS) is a complex and multifactorial 
problem. Therefore, a large number of different 
variables are being used for the evaluation of patients 
with this disease. Guidelines of the ARA [1] and 
European League Against Rheumatism (EULAR) [2] 
for clinical trials in AS have been developed. However, 
the validity, reproducibility and the mutual relation­
ship of this large number of variables have not been 
studied [3, 4], with the exception of some variables [5]. 
Laboratory variables, e.g. C-reactive protein (CRP), 
ESR and IgA, are not abnormal in every patient with 
active disease [6-14], and primarily appear to be 
associated with peripheral arthritis [15, 16] and 
extra-articular features [17]. Another major problem is 
the lack of sensitivity to change, especially in those 
variables measuring spinal mobility [2] 
by the
combination of momentary disease activity, i.e. process 
of the disease, and of the result, i.e. outcome of the 
disease. As a result of these problems, a wide variety 
of variables are used in clinical trials on AS, making 
comparison between different studies difficult.
The aim of this study was to evaluate the validity of 
commonly used variables for the assessment of disease 
activity in AS. Data from two clinical longitudinal 
prospective studies, in which patients had to have a 
high active disease upon study entry, were used. The 
results of this evaluation bring within reach the
that commonly used va rii
Submitted 7 July 1995; revised version accepted 4 March 1996. 
Correspondence to: M, Creemers, Department of Rheumatology, 
University Hospital Nijmegen, St Radboud, PO Box 9101, 6500 HB 
Nijmegen, The Netherlands.
selection of a core set of variables which are reliable,
thisreproducible and sensitive to change, 
might lead to the development of a disease activity 
score for AS.
PATIENTS AND METHODS
Patients
Records of AS patients participating in two 
prospective longitudinal studies were used. Patients of
sex, aged between 18 and 60 yr, had to fulfil the 
modified New York criteria [18]. Patients participated 
either in a 48 week double-blind NSAID study
(n 59), entering after a washout period for NSAIDs, 
or a 24 week open study with methotrexate (MTX), in 
which patients had to have failure of treatment with
[19]. In bothand asalazine
studies, patients had to have active disease, defined as 
a clear need for anti-inflammatory, analgesic drug. In 
addition, they had to have at least two of the following 
features: ( I ) spinal pain, (2) morning stiffness of at least 
30 min; (3) chest pain; (4) pain in both buttocks; (5) 
peripheral arthritis; (6) raised ESR ^ 30 mm/1st h or 
CRP > 20 mg/1 or IgA ^ 3.9 mg/1, 
participated first in the NSAID study and subsequently 
in the MTX study, only data from the MTX study of 
these patients were considered. Two other patients were 
retrospectively excluded from the NSAID study 
because they did not meet the above-described criteria 
for active disease. In total, there were 65 patients (48 
men, 17 female); 62 of them were HLA-B27 positive, 
six had peripheral arthritis and four iridocyclitis. Mean 
age was 38 yr (s.D. = 9), mean disease duration 9 yr
(S.D. 8). Features present at study entry are shown in
Table I. In Fig. 1, the number of patients and the
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F ig. 1.— Numbers o f  features present for active disease in 65 patients.
numbers o f  features present _ for active disease are 
shown. Figure 2 shows the division o f patients and the 
degree of pain and stiffness.
M easurem ents
For measurement o f  disease activity, the following 
variables were assessed at every visit.
Clinical var ’‘S . Occiput-to-wall distance,
measured in centimetres with the patient standing as 
erect as possible with heels and back against the wall; 
chest expansion: the difference in centimetres between 
the circumference o f the chest at nipple line on full 
inspiration and full expiration; Schober 10 cm index 
[20]; modified Schober 15 cm index [5]; lumbar flexion
index [2 1 ]; iingertip-lo-lloor distance: the distance in 
centimetres between the third finger and the floor with 
the patient bending forward maximally, without flexing 
the knees; lumbar lateral flexion [2 2 ], as a percentage 
o f  body height; the number o f  swollen joints; enthesis 
index [23], maximal score being 90; root joint index: 
pain o f  shoulders and hips on palpation and/or passive 
movement was assessed with pain graded from 0 to 3 
and the sum o f  the scores being the index; mobility of  
the cervical spine (in degrees): rotation using a
, and lateral 
retroflexion using a hydrogoniometer.
and
ctive variables. Spinal during the day,
spinal pain during the night and general wellbeing were
by using a 1 0 0  mm visual analogue scale
ness(VAS); duration o f  morning 
recorded in minutes with a maximum of 360 min.
rising,
TABLE I
Features of active disease present at i •y of all 65 patients
Feature Number of patients
Spinal pain 62
Morning stillness ^3 0  min 59
Chest pain 29
Buttock pain 24
Raised ESR/IgA/CRP* 48
* HSR ^  30 mm or CR ^  20 mg/1 or IgA ^  3.9 mg/1.
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Flo. 2. Division of the degree of pain and morning stiffness.
Laboratory var 's. ESR, C-reactive protein,
complete blood cell count, IgA, G and M.
Functional assessm ent. A Dutch functional index for 
AS [24], in essence a modification of the functional
atindex o f Dougados et a/. [25, 26] was com  
week 0 and every 12 weeks. The maximum score was 
four.
Variables which have been measured on both sides, 
i.e. lumbar lateral flexion, cervical rotation and cervical 
lateral flexion, were reported as a good and bad score 
for each patient irrespective o f  the side.
Definition o f  disease activ ity  and selection o f  records 
Patients were seen 12 times in the N SA ID  study and 
eight times in the M TX study. This resulted in 736 
records for these 65 patients. Patients’ records were
guided by the definitions o f  high and low 
disease activity. Disease activity was defined as low in 
the NSAID study if patients had used a stable dose o f  
N SA ID s for at least 24 weeks, and in the MTX study 
if patients continued M TX after 24 weeks. Disease 
activity was defined as high at week 0  o f both studies;
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TABLE 11
and 90 of assessed variables (101 records)
Variable plO Median p90 Skewness Skewness after transformation
Spinal pain at night (VAS) 6 37 82 0.19
Spinal pain during the day (VAS) 6 46 82 0.04 ** -
General wellbeing (VAS) 10 46 84 0.14
Morning stiffness (minutes) 0 60 144 2.34 0.08 (sqrt)
Fingertip-to-floor distance (cm) 0 16 41 0.62 g ,v —'
Lumbar flexion index (cm) 17.0 20.0 22.0 -  0.40 ;• ^ .. -
Modified Schober index (cm) 17.0 20.0 21.5 — 0.25
Schober 10 cm index (cm) 11.0 14.0 15.0 -  0.37
Lateral flexion good side (%) 1.75 4.17 y.38 0.83
Lateral flexion bad side (%) 2.20 5.14 10.17 0.69 >• *!..
Occiput-to-wall distance (cm) 0 1 10 1.75 0,62 (sqrt)
Chest expansion (cm) 2.0 3.5 6.0 1.02 0,76 (In)
Cervical mobility (degrees) 
Anteflexion 16 52 71 -  0.30
Retroflexion 20 42 68 0.11 , ....
Lateral flexion good side 13 V 48 0.05
Lateral flexion bad side 14 40 58 -  0.04
Rotation good side 30 62 «0 -  0.69 * « * 4*. t
Rotation bad side 40 70 84 -  1.08
Enthesis index 0 7 29 1.97 0.34 (sqrt)
Root joint index 0 0 2 3.28 1.29 (d-sqrt)
Dutch functional index 0.24 1.12 1 17 to k f 0.20
Number of swollen joints 0 0 1 5.40 2.26 (d-sqrt)
ESR (mm/ 1st h) 6 15 53 1.92 -  0.09 (In)
C-reactive protein (mg/1) 4 19 51 3.61 -  0.20 (In)
Platelets (1071) 217 274 405 1.53 0.26 (In)
IgA (mg/1) 1.61 2.74 5.15 0.77 ---------
IgG (mg/1) 8.50 11.28 17.60 3.19 1.04 (In)
IgM (mg/l) 0.80 1.74 2.74 0.72 . < ta
VAS, visual analogue scale; ESR, erythrocyte sedimentation rate; In, logarithmic transformation; sqi't, square root transformation; d-sqrt, 
double square root transformation.
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Assessor
TABLE III
Factors out of principal component analysis and reliability analysis
Patient Laboratory
1. ‘Cervical mobility’
Cervical anteflexion 
Cervical retroflexion 
Cervical rotation g 
Cervical rotation b 
Cervical lateral flexion g 
Cervical lateral flexion b
7. ‘Subjective complaints’ 
Spinal pain day 
Spinal pain night 
General wellbeing 
Morning stiffness
9. ‘Inflammatory response’
ESR
CRP
IgG
Platelets
2. 'Lumbar flexion’ 
Modified Schober 
Lumbar flexion index 
Schober 10 cm index
8. Functional index 10. IgA
3. Enthesis index 11. IgM
4. Root joints
5. Swollen joints
6. ‘Spinal mobility’
Fingertip-to-floor distance 
Occiput-to-wall distance 
Lumbar lateral flexion g 
Lumbar lateral flexion b
g, good side; b, bad side.
o f  all composed factors varied from 0.82 to 0.97 and 
may be considered as reliable. Finally, there were 11 
factors: cervical mobility (Factor 1), lumbar flexion 
(Factor 2), the enthesis index (Factor 3), the root joints 
(Factor 4), swollen joints (Factor 5), ‘spinal mobility’ 
(Factor 6 ), "subjective complaints’ (Factor 7), the 
functional index (Factor 8 ), ‘inflammatory response’ 
(Factor 9), IgA (Factor 10) and IgM (Factor 11) (see 
Table III).
Variables were scaled, and scaling factors were 
chosen to equalize the s .d . o f variables within each 
factor. Factor values then were calculated as the mean 
of the variables corresponding with the factor.
Discriminant 'S IS
Paired /-testing was performed on the factor values 
of the records o f 36 patients with observations both
with a high and low ase activity. For further
analysis, Factor 1 was excluded because no significant 
change was found (P  =  0.16). The number o f  swollen 
joints also showed no significant change (P  =  0.06); as 
this was possibly due to the small number o f  patients 
with peripheral arthritis, we did not exclude this factor.
The stepwise forward discriminant analysis showed 
five significant steps entering: ‘subjective complaints’ 
(Factor 7), ‘inflammatory response’ (Factor 9), root 
joints (Factor 4), enthesis index (Factor 3) and IgA 
(Factor 10). Table IV shows the relative importance o f  
factors and variables used in the discriminant analysis. 
Canonical correlation was 0.64 and 80% were correctly 
classified.
The discriminating power, computed as the stan­
dardized differences from paired /-testing o f  the 36 
patients, and the correlations with the discriminant 
score ( 1 0 1  records) gave similar information about the 
factors used in the analyses (see Table IV).
Disease duration
Variables and factor values from the N SA ID  study 
o f  weeks 0  and 1 2  and corresponding differences were 
used for the calculation of Spearman rank correlations 
with disease duration. Only statistically significant 
correlations are shown in Table V.
In longitudinal studies, the quality of variables can 
be determined by the calculation o f interperiod 
correlations. These intercorrelations can be plotted 
against time interval and a regression line can be 
calculated. The intersection o f  this line with the vertical 
axis (intercept) is an estimation of the direct 
measurement-remeasurement correlation (r(1) and this
TABLE IV
Correlations of 11 factors with discriminant score and discriminating
power
Correlations with Standardized
discriminant difference
sco re (72 paired
Factor (101 records )t records^
Subjective complaints* (F 7) 0.84 1.17
Enthesis index’’* (F 3) 0.63 0.89
Functional index (F 8) 0.56 0.69
Spinal mobility (F 6) -  0.42 0.46
Root joints* (F 4) 0.38 0.50
Lumbar flexion (F 2) 0.30 0.44
Inflammatory response* (F 9) — 0.24 0.33
IgM (F 11) 0.17 0.40
Swollen joints (F 5) 0.12 0.34
IgA* (F 10) 0.10 0.25
Cervical mobility (F 1) 0.16
F, factor (see Table 
^Factors selected i 
*1*65 patients.
$36 patients.
in discriminant am
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TABLE V
Analyses used for selection of variables
Correlations with
Discriminating power Reproducibility disease duration
standardized difference estimated n>
Factors and variables Selected for AS-DAS (/» =  36) (it =  59) week 0 week 12
‘Cervical mobility’ 0.16
Anteflexion 0.11 0.77 — 0.32*
Retroflexion — 0.01 0.81
rotation g 0.29* 0.82
rotation b 0.29 * 0,80
lateral flexion g 0.06 0.87
lateral flexion b V -  H  \ 0.05 0.86
‘Lumbar flexion’ 0.44***
Lumbar flexion index (X) 0.63**** 0.88
Modified Sehober index 0.30**** 0.87
Schober 10 cm index 0.35*** 0.85
‘Subjective complaints’ J
Spinal pain during the day X 1.06**** 0.65
Spinal pain at night ,— 0.83**** 0.63
General wellbeing —- j j i *#*+ 0.58
Morning stiffness — 0.75**** 0.55
Enthesis index X Q g Q * * * * 0.74
Functional index X 0.69**** 0.92
‘Inflammatory response’ 0.33****
ESR »■ n n 0.17 0.87
CRP X 0.72 0.74
IgG — 0.23 0.86
Platelets 0.02 0.85
IgA 0.25*** 0.94
IgM 0.40**** 0.95 -  0.28*
Root joints X 0.50* 0.67
Swollen joints (X) 0.341’“1""' 0.80
‘Spinal mobility’ 0.46**** -  0.30* -  0.37****
Fingertip-to-floor distance M .  H 0.44**** 0.94
Occiput-to-wall distance 0.31*** 0.89 0.27* 0.27*
Lumbar lateral flexion g ----- 0.31**** 0.94 -  0.33**
Lumbar lateral flexion b I . . , - !  > 0.31**** 0.94 -  0.27* -  0.35****
Chest expansion H 0.34*** 0 . 8 6
ESR, erythrocyte sedimentation rate; CRP, C-reaetive 
*P <  0.05; **/> <  0.01; ***ƒ> < 0.005; ****/> <  0.001. 
X = selected variable.
in; b, bad side; g, g side.
may be interpreted as a quality measure of a variable 
[28]. Estimated ru o f variables belonging to composed 
factors are shown in Table V.
enthesis index; (5) swollen joints; (6) functional index;
(7) CRP.
Composition o f  a disease activity  score 
A forward stepwise discriminant analysis on 
seven selected process variables resulted in a corre­
lation with a discriminant score of 0.07 for swollen 
reproducibility and a lack o f  correlation with disease joints (Factor 5), while the remaining six variables had
correlations of at least 0.35. Therefore, this variable
Selection o f  a core set o f  variables 
The selection of useful process variables is based 
on discriminating power (standardized
was left out of ation.
duration. Factors and variables correlating with 
disease duration were considered assessing primarily 
outcome and not selected. For reasons of simplicity 
and practicality, only one single variable out o f  a 
composed factor was selected. The selection o f  factors 
and variables was based on the largest discriminating 
power (standardized difference) and reproducibility unstable, i.e. its discriminating power is completely 
(measurement-remeasurement correlation, r0). Vari- expressed by the other (interrelated) variables. Finally, 
ables with standardized differences o f  <0 .30  were not
discriminant analysis showed a positive coefficient for 
the lumbar flexion index and a negative correlation 
with the discriminant score. Because o f  
crepancy, this variable
the ankylosing spondylitis I«/*
taken into account. Selected process variables are thus (AS-DAS) was computed with a discriminant analysis
(marked in Table V); (1) spinal pain during the day 
(VAS); (2) lumbar flexion index; (3) root joints; (4)
using assessor, patient and laboratory variables (in 
total five), namely spinal pain during the day (VAS),
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TABLE VI
Computation of the ankylosing spondylitis disease activity score (AS-DAS), medians and percentiles 10 and 90 of the live selected variables
Correlation with
High disease activity’1' (n =  55)J Low disease activity* (n = 46)
discriminant score Coefficient Pio Pío Pw Pio Pjo Pw
Functional index 0.69 0.238 0.50 1.41 2.18 0.02 0.62 1.76
Enthesis index (sqrt)f 0,58 0.113 0 16 36 0 2 22
Spinal pain during the day 0.51 0.318 26 62 86 3 23 70
CRP (ln)t 0.43 6.540 7 24 75 3 12 35
Root joints (d-sqrt)f 0.35 5.245 0 0 2 0 0 1
Computed AS-DAS 30.9 44.7 60.6 13.3 26.8 40.0
d-
Computation: AS-DAS = 0.238 x (functional index) + 1.13 x sqrt (enthesis index) +  0.318 x (spinal pain) + 6.54 x In
sqrt (root joints).
*Percentiles.
I'Transformation: In = logarithmic; sqrt = square root; d-sqrt 
±Number of records.
double square root.
+ 5.245 x
enthesis index, functional index, root joints and CRP. 
Three variables had to be transformed to obtain 
normality for this analysis. Correlations with the final 
score, means and s .d . o f the separate variables and 
coefficients for the final formula are shown in Table VI. 
The canonical correlation was 0.67 and 82% were 
correctly classified in this final discriminant analysis.
D ISC U SSIO N
Judgement o f disease activity in rheumatic diseases 
is a complex process and forms the basis of clinical 
decisions. Assessed variables are often a combination 
o f  process and outcome o f  the disease. In AS, 
commonly used variables contain a lot o f interpret­
ation problems, as stated in the Introduction. In the 
past, some indices o f  disease activity in AS  
been proposed, based on clinical judgement [29-33]. 
However, the majority o f these indices have not been 
validated. Recently, Salaffi et al. [34] analysed data on 
45 AS patients in order to identify groups o f  variables 
out o f  the large number available. Three groups o f  
variables were identified, measuring disease activity, 
damage and functional status, the latter being a 
combination o f  disease activity and disease outcome.
In our study longitudinal data on AS patients were 
analysed to identify those variables which discriminate 
for disease activity. Since no ‘gold standard’ for disease 
activity in AS is available, pre-defined criteria for high 
and low disease activity were used. Two groups o f  
patients’ records were formed: one group with high and 
one group with low disease activity. For evaluation o f  
reproducibility, discriminating power and the corre- 
ation of variables and factors with disease duration, a 
pre-defined analysis strategy [35], including principal 
component analysis to form subgroups of reliable, 
interrelated variables, reliability o f factors was used. 
This evaluation resulted in a selection of seven process 
variables. Finally, a disease activity score was 
computed o f  five variables, derived from a discrimant 
analysis.
The core set o f  seven process variables encompassed 
the lumbar flexion index, spinal pain during the day, 
enthesis index, functional index, CRP, root joints and 
the number o f  swollen joints, comprising assessor and 
laboratory variables as well as patient variables. In a
discriminant score for the construction of a disease 
activity score, two variables had to be excluded: (a) 
‘swollen joints’ because o f  a low correlation with the 
discriminant score and (b) ‘the lumbar flexion index’, 
which appeared to be an unstable variable, i.e. its 
discriminating power is completely expressed by the 
other (interrelated) variables. It is striking that pain 
assessed in three o f these variables, in 2 , gives most 
weight to the A S-D A S.
In conclusion, the proposed A S-D A S should be 
validated further. For standardization purposes, the 
selected core set o f  process variables should be used in 
future clinical trials in AS, resulting in improvement o f  
the comparability o f different studies. Additionally, the 
problem o f  multiple statistical testing will be solved 
since only a reduced number o f  variables, and eventu­
ally a single com posed variable, i.e. the AS-DAS, have 
to be analysed for the evaluation of disease activity.
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